Fig. 5

A-C) DI TNC1 cells were treated with 1 µM Aβ peptide for 24 h, and Aβ with SPL and YPL, and compared to untreated controls. A, B Immunolabeling of Aβ peptides using anti-Aβ antibodies reveals a reduction in the number of Aβ positive signals after treatment with PLs (one-way ANOVA, p=0.0037; Tukey post-hoc test: Aβ vs. Aβ+SPL p=0.044; Aβ vs. Aβ+YPL p=0.0247, n=10). B Exemplary images of Aβ signals after treatments. C, D Thioflavin labeling of Aβ shows no significant reduction in the number of Aβ aggregates (C) (one-way ANOVA), but a reduction in the Aβ aggregate size after SPL treatment (one-way ANOVA, p= 0.0141; Tukey post-hoc test: Aβ vs. Aβ+SPL p=0.0138, n=10) A reduction in Aβ aggregate size was also observed after YPL treatment, although not statistically significant (Tukey post-hoc test: Aβ vs. Aβ+YPL p= 0.0568, n=10) (D). E-G Primary hippocampal neurons were grown for 11 days and exposed to the media (secretomes) of astrocytes (untreated, treated with Aβ, treated with SPL or YPL plus Aβ, and treated with SPL or YPL only). After 4 days, the percentage of apoptotic cells per total cells in the culture was calculated. E The secretome of astrocytes exposed to SPL and Aβ caused significantly less effect on cell health compared to the secretome of astrocytes exposed to Aβ-only treatment (one-way ANOVA, p=0.012; Tukey post-hoc test: Aβ vs. Aβ+SPL p=0.00682, n=6-8 optic fields of view). F No effect on cell health was observed after exposure of neurons to the secretomes of astrocytes treated with SPL or YPL only. G Exemplary images of Annexin V FITC signals after treatments. White arrows indicate apoptotic cells. B, G Scale bar = 30 μm